SRZN

SEC source: 0000950170-24-042636 · ownership.xml · nonDerivative · entry 2

Kutzkey Tim · CIK 0001614186 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By The Column Group III-A, LP

Disclosed balance after: 332,885

F1 · price: Represents a price per unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which The Column Group III, LP ("TCG III LP") and The Column Group III-A, LP ("TCG III-A LP") purchased in the Issuer's private placement on April 4, 2024.

F3 · ownership.nature: The securities are directly held by TCG III-A LP. TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

SEC source: 0000950170-24-042636 · ownership.xml · nonDerivative · entry 1

Kutzkey Tim · CIK 0001614186 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By The Column Group III, LP

Disclosed balance after: 294,767

F1 · price: Represents a price per unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which The Column Group III, LP ("TCG III LP") and The Column Group III-A, LP ("TCG III-A LP") purchased in the Issuer's private placement on April 4, 2024.

F2 · ownership.nature: The securities are directly held by TCG III LP. The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and the Reporting Person, a member of the Issuer's board of directors (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

SEC source: 0000950170-24-045118 · ownership.xml · nonDerivative · entry 2

COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner

COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner

COLUMN GROUP III, LP · CIK 0001668159 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By The Column Group III-A, LP

Disclosed balance after: 326,992

F1 · price: Represents a price per unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which The Column Group III, LP ("TCG III LP") and The Column Group III-A, LP ("TCG III-A LP") purchased in the Issuer's private placement on April 4, 2024.

F2 · balance_after: This Form 4/A is being filed to correct the amount beneficially owned by the Reporting Person, which was misreported in the original Form 4 filed on April 8, 2024 due to an administrative error.

F4 · ownership.nature: The securities are directly held by TCG III-A LP. TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

SEC source: 0000950170-24-045118 · ownership.xml · nonDerivative · entry 1

COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner

COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner

COLUMN GROUP III, LP · CIK 0001668159 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By The Column Group III, LP

Disclosed balance after: 289,549

F1 · price: Represents a price per unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which The Column Group III, LP ("TCG III LP") and The Column Group III-A, LP ("TCG III-A LP") purchased in the Issuer's private placement on April 4, 2024.

F2 · balance_after: This Form 4/A is being filed to correct the amount beneficially owned by the Reporting Person, which was misreported in the original Form 4 filed on April 8, 2024 due to an administrative error.

F3 · ownership.nature: The securities are directly held by TCG III LP. The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

SEC source: 0000950170-24-045110 · ownership.xml · nonDerivative · entry 2

Kutzkey Tim · CIK 0001614186 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By The Column Group III-A, LP

Disclosed balance after: 326,992

F1 · price: Represents a price per unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which The Column Group III, LP ("TCG III LP") and The Column Group III-A, LP ("TCG III-A LP") purchased in the Issuer's private placement on April 4, 2024.

F2 · balance_after: This Form 4/A is being filed to correct the amount beneficially owned, which was misreported in the original Form 4 filed on April 8, 2024 due to an administrative error.

F4 · ownership.nature: The securities are directly held by TCG III-A LP. TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

SEC source: 0000950170-24-045110 · ownership.xml · nonDerivative · entry 1

Kutzkey Tim · CIK 0001614186 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By The Column Group III, LP

Disclosed balance after: 289,549

F1 · price: Represents a price per unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which The Column Group III, LP ("TCG III LP") and The Column Group III-A, LP ("TCG III-A LP") purchased in the Issuer's private placement on April 4, 2024.

F2 · balance_after: This Form 4/A is being filed to correct the amount beneficially owned, which was misreported in the original Form 4 filed on April 8, 2024 due to an administrative error.

F3 · ownership.nature: The securities are directly held by TCG III LP. The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and the Reporting Person, a member of the Issuer's board of directors (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

SEC source: 0001593968-24-000209 · primary_01.xml · derivative · entry 1

Parker Craig C · CIK 0001526064 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33

Underlying: Common Stock · 33 shares

Expires 2034-01-29

F1 · derivative.exercise_date: The shares subject to the options vest and become exercisable in a series of 48 equal monthly installments beginning on 2/1/2024, subject to the reporting person's continued employment through the applicable vesting date.

SEC source: 0001593968-23-001519 · primary_01.xml · nonDerivative · entry 1

Williams Charles O · CIK 0001325818 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,085

F1 · kind: This reporting person is voluntarily reporting these shares acquired under the Surrozen, Inc. 2021 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

F2 · shares: On December 13, 2023, Surrozen, Inc. effected a one-for-fifteen reverse stock split of its outstanding common stock (the "Reverse Stock Split"). All amounts of securities listed herein have been adjusted to reflect the effect of the Reverse Stock Split.

SEC source: 0001593968-23-001517 · primary_01.xml · nonDerivative · entry 1

Parker Craig C · CIK 0001526064 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,046

F1 · kind: This reporting person is voluntarily reporting these shares acquired under the Surrozen, Inc. 2021 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

F2 · shares: On December 13, 2023, Surrozen, Inc. effected a one-for-fifteen reverse stock split of its outstanding common stock (the "Reverse Stock Split"). All amounts of securities listed herein have been adjusted to reflect the effect of the Reverse Stock Split.

SEC source: 0001593968-23-001518 · primary_01.xml · nonDerivative · entry 1

Li Yang · CIK 0001990537 · Exec. Vice President, Research

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,085

F1 · kind: This reporting person is voluntarily reporting these shares acquired under the Surrozen, Inc. 2021 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

F2 · shares: On December 13, 2023, Surrozen, Inc. effected a one-for-fifteen reverse stock split of its outstanding common stock (the "Reverse Stock Split"). All amounts of securities listed herein have been adjusted to reflect the effect of the Reverse Stock Split.

SEC source: 0001593968-23-001020 · primary_01.xml · nonDerivative · entry 1

Yeh Wen-Chen · CIK 0001873360 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,216

F1 · kind: These shares were acquired under the Surrozen, Inc. 2021 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

SEC source: 0001593968-23-001019 · primary_01.xml · nonDerivative · entry 1

Williams Charles O · CIK 0001325818 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,578

F1 · kind: These shares were acquired under the Surrozen, Inc. 2021 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

SEC source: 0001593968-23-001021 · primary_01.xml · nonDerivative · entry 1

Parker Craig C · CIK 0001526064 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,578

F1 · kind: These shares were acquired under the Surrozen, Inc. 2021 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

SEC source: 0001593968-23-000843 · primary_01.xml · derivative · entry 1

WOODHOUSE DAVID J · CIK 0001642995 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2033-05-18

SEC source: 0001593968-23-000839 · primary_01.xml · derivative · entry 1

CHAI CHRISTOPHER Y · CIK 0001413823 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2033-05-18

SEC source: 0001593968-23-000837 · primary_01.xml · derivative · entry 1

BJERKHOLT ERIC · CIK 0001197350 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2033-05-18

SEC source: 0001593968-23-000841 · primary_01.xml · derivative · entry 1

Kutzkey Tim · CIK 0001614186 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2033-05-18

SEC source: 0001593968-23-000844 · primary_01.xml · derivative · entry 1

Lin Shao-Lee · CIK 0001725092 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2033-05-18

SEC source: 0001593968-23-000842 · primary_01.xml · derivative · entry 1

Rothenberg Mace · CIK 0001873988 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2033-05-18

SEC source: 0001593968-23-000838 · primary_01.xml · derivative · entry 1

Haak-Frendscho Mary · CIK 0001873902 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2033-05-18

SEC source: 0000950170-23-023326 · ownership.xml · derivative · entry 1

Berkenblit Anna · CIK 0001691868 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2033-05-18

F1 · security: The options fully vest and become exercisable on the one-year anniversary of the grant date, subject to the reporting person's continuous service as a director.

SEC source: 0001593968-23-000390 · primary_01.xml · derivative · entry 1

Parker Craig C · CIK 0001526064 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 405,000

Underlying: Common Stock · 405,000 shares

Expires 2033-03-01

F1 · derivative.exercise_date: The shares subject to the options vest and become exercisable in a series of 48 equal monthly installments beginning on 2/1/2023, subject to the reporting person's continued employment through the applicable vesting date.

SEC source: 0001593968-23-000264 · primary_01.xml · derivative · entry 1

Yeh Wen-Chen · CIK 0001873360 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,000

Underlying: Common Stock · 125,000 shares

Expires 2033-02-01

F1 · derivative.exercise_date: The shares subject to the options vest and become exercisable in a series of 48 equal monthly installments beginning on 2/1/2023, subject to the reporting person's continued employment through the applicable vesting date.

SEC source: 0001593968-23-000265 · primary_01.xml · derivative · entry 1

Williams Charles O · CIK 0001325818 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,000

Underlying: Common Stock · 125,000 shares

Expires 2033-02-01

F1 · derivative.exercise_date: The shares subject to the options vest and become exercisable in a series of 48 equal monthly installments beginning on 2/1/2023, subject to the reporting person's continued employment through the applicable vesting date.

SEC source: 0001593968-22-001750 · primary_01.xml · nonDerivative · entry 1

Yeh Wen-Chen · CIK 0001873360 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 229,138

F1 · kind: These shares were acquired under the Surrozen, Inc. 2021 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

SEC source: 0001593968-22-001745 · primary_01.xml · nonDerivative · entry 1

Williams Charles O · CIK 0001325818 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,578

F1 · kind: These shares were acquired under the Surrozen, Inc. 2021 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

SEC source: 0001593968-22-001749 · primary_01.xml · nonDerivative · entry 1

Parker Craig C · CIK 0001526064 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,578

F1 · kind: These shares were acquired under the Surrozen, Inc. 2021 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

SEC source: 0001593968-22-001746 · primary_01.xml · nonDerivative · entry 1

Vanhove Geertrui · CIK 0001771994 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,412

F1 · kind: These shares were acquired under the Surrozen, Inc. 2021 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

SEC source: 0000899243-22-038571 · doc4.xml · derivative · entry 8

BLUTT MITCHELL J MD · CIK 0001097955 · 10% owner

Soffer Benny · CIK 0001829318 · 10% owner

Livingston Kevin Harold · CIK 0001828234 · 10% owner

Consonance Capital Management LP · CIK 0001544773 · 10% owner

Consonance Capman GP, LLC · CIK 0001620428 · 10% owner

Consonance Life Sciences · CIK 0001824774 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Consonance Life Sciences, LLC

Disclosed balance after: 0

Underlying: Common Stock · 144,666 shares

Expires not disclosed

F9 · price: Pursuant to the Purchase Agreement, Consonance Life Sciences agreed to sell to the Issuer 1,885,000 shares of common stock of the Issuer and warrants to purchase 144,666 shares of common stock of the Issuer for an aggregate purchase price of $942,500. Each warrant entitles the holder thereof to purchase one share of common stock of the Issuer at a price of $11.50 per share, subject to adjustment. The warrants are currently exercisable and will expire at the earlier of August 12, 2026, or upon redemption or liquidation.

F9 · derivative.exercise_date: Pursuant to the Purchase Agreement, Consonance Life Sciences agreed to sell to the Issuer 1,885,000 shares of common stock of the Issuer and warrants to purchase 144,666 shares of common stock of the Issuer for an aggregate purchase price of $942,500. Each warrant entitles the holder thereof to purchase one share of common stock of the Issuer at a price of $11.50 per share, subject to adjustment. The warrants are currently exercisable and will expire at the earlier of August 12, 2026, or upon redemption or liquidation.

F9 · derivative.expiration_date: Pursuant to the Purchase Agreement, Consonance Life Sciences agreed to sell to the Issuer 1,885,000 shares of common stock of the Issuer and warrants to purchase 144,666 shares of common stock of the Issuer for an aggregate purchase price of $942,500. Each warrant entitles the holder thereof to purchase one share of common stock of the Issuer at a price of $11.50 per share, subject to adjustment. The warrants are currently exercisable and will expire at the earlier of August 12, 2026, or upon redemption or liquidation.

F10 · ownership.nature: Consonance Life Sciences is governed by a board of managers consisting of Mitchell J. Blutt, Benny Soffer and Kevin Livingston. As such, Mitchell J. Blutt, Benny Soffer and Kevin Livingston may be deemed to have voting and investment discretion over the securities held by Consonance Life Sciences and may be deemed to have shared beneficial ownership of such securities. Each of Mitchell J. Blutt, Benny Soffer and Kevin Livingston disclaims beneficial ownership of the securities that were held by Consonance Life Sciences except to the extent of their pecuniary interest therein. The Master Account, Consonance Opportunity Master and the Managed Account in the aggregate own the majority of the unit interests in Consonance Life Sciences.

SEC source: 0000899243-22-038571 · doc4.xml · derivative · entry 7

BLUTT MITCHELL J MD · CIK 0001097955 · 10% owner

Soffer Benny · CIK 0001829318 · 10% owner

Livingston Kevin Harold · CIK 0001828234 · 10% owner

Consonance Capital Management LP · CIK 0001544773 · 10% owner

Consonance Capman GP, LLC · CIK 0001620428 · 10% owner

Consonance Life Sciences · CIK 0001824774 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Managed Account

Disclosed balance after: 0

Underlying: Common Stock · 150,275 shares

Expires not disclosed

F7 · price: Pursuant to the Purchase Agreement, the Managed Account agreed to sell to the Issuer 450,827 shares of common stock of the Issuer and warrants to purchase 150,275 shares of common stock of the Issuer for an aggregate purchase price of $225,413.50. Each warrant entitles the holder thereof to purchase one share of common stock of the Issuer at a price of $11.50 per share, subject to adjustment. The warrants are currently exercisable and will expire at the earlier of August 12, 2026, or upon redemption or liquidation.

F7 · derivative.exercise_date: Pursuant to the Purchase Agreement, the Managed Account agreed to sell to the Issuer 450,827 shares of common stock of the Issuer and warrants to purchase 150,275 shares of common stock of the Issuer for an aggregate purchase price of $225,413.50. Each warrant entitles the holder thereof to purchase one share of common stock of the Issuer at a price of $11.50 per share, subject to adjustment. The warrants are currently exercisable and will expire at the earlier of August 12, 2026, or upon redemption or liquidation.

F7 · derivative.expiration_date: Pursuant to the Purchase Agreement, the Managed Account agreed to sell to the Issuer 450,827 shares of common stock of the Issuer and warrants to purchase 150,275 shares of common stock of the Issuer for an aggregate purchase price of $225,413.50. Each warrant entitles the holder thereof to purchase one share of common stock of the Issuer at a price of $11.50 per share, subject to adjustment. The warrants are currently exercisable and will expire at the earlier of August 12, 2026, or upon redemption or liquidation.

F8 · ownership.nature: Consonance Management was an indirect beneficial owner of the securities reported herein that were held by the Managed Account. Consonance Management is the investment adviser of the Managed Account and exercises voting and investment power over the securities of the Issuer held by the Managed Account. Capman is the general partner of Consonance Management. Consonance Management receives an asset-based fee, but has no pecuniary interest. Mitchell Blutt is the manager and member of Capman. Each of Dr. Blutt, Consonance Management and Capman disclaims beneficial ownership of the securities that were held by the Managed Account except to the extent of their pecuniary interest therein.

SEC source: 0000899243-22-038571 · doc4.xml · derivative · entry 6

BLUTT MITCHELL J MD · CIK 0001097955 · 10% owner

Soffer Benny · CIK 0001829318 · 10% owner

Livingston Kevin Harold · CIK 0001828234 · 10% owner

Consonance Capital Management LP · CIK 0001544773 · 10% owner

Consonance Capman GP, LLC · CIK 0001620428 · 10% owner

Consonance Life Sciences · CIK 0001824774 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Consonance Capital Opportunity Master Fund, LP

Disclosed balance after: 0

Underlying: Common Stock · 432,639 shares

Expires not disclosed

F4 · price: Pursuant to the Purchase Agreement, Consonance Opportunity Master agreed to sell to the Issuer 1,297,922 shares of common stock of the Issuer and warrants to purchase 432,639 shares of common stock of the Issuer for an aggregate purchase price of $648,961. Each warrant entitles the holder thereof to purchase one share of common stock of the Issuer at a price of $11.50 per share, subject to adjustment. The warrants are currently exercisable and will expire at the earlier of August 12, 2026, or upon redemption or liquidation.

F4 · derivative.exercise_date: Pursuant to the Purchase Agreement, Consonance Opportunity Master agreed to sell to the Issuer 1,297,922 shares of common stock of the Issuer and warrants to purchase 432,639 shares of common stock of the Issuer for an aggregate purchase price of $648,961. Each warrant entitles the holder thereof to purchase one share of common stock of the Issuer at a price of $11.50 per share, subject to adjustment. The warrants are currently exercisable and will expire at the earlier of August 12, 2026, or upon redemption or liquidation.

F4 · derivative.expiration_date: Pursuant to the Purchase Agreement, Consonance Opportunity Master agreed to sell to the Issuer 1,297,922 shares of common stock of the Issuer and warrants to purchase 432,639 shares of common stock of the Issuer for an aggregate purchase price of $648,961. Each warrant entitles the holder thereof to purchase one share of common stock of the Issuer at a price of $11.50 per share, subject to adjustment. The warrants are currently exercisable and will expire at the earlier of August 12, 2026, or upon redemption or liquidation.

F5 · ownership.nature: Consonance Management was an indirect beneficial owner of the securities reported herein that were held by Consonance Opportunity Master. Consonance Management is the investment adviser of Consonance Opportunity Master, and pursuant to an investment advisory agreement, Consonance Management exercises voting and investment power over the securities of the Issuer held by Consonance Opportunity Master. Capman is the general partner of Consonance Management.

F6 · ownership.nature: (Continued from Footnote 5) Consonance Management receives an asset-based fee, but has no pecuniary interest. Mitchell Blutt is the manager and member of Capman and has a pecuniary interest in the securities held by Consonance Opportunity Master as the manager and member of the general partner of Consonance Opportunity Master and thereby is entitled to a portion of the profits allocation. Each of Dr. Blutt, Consonance Management and Capman disclaims beneficial ownership of the securities that were held by Consonance Opportunity Master except to the extent of their pecuniary interest therein.

SEC source: 0000899243-22-038571 · doc4.xml · derivative · entry 5

BLUTT MITCHELL J MD · CIK 0001097955 · 10% owner

Soffer Benny · CIK 0001829318 · 10% owner

Livingston Kevin Harold · CIK 0001828234 · 10% owner

Consonance Capital Management LP · CIK 0001544773 · 10% owner

Consonance Capman GP, LLC · CIK 0001620428 · 10% owner

Consonance Life Sciences · CIK 0001824774 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Consonance Capital Master Account LP

Disclosed balance after: 0

Underlying: Common Stock · 582,916 shares

Expires not disclosed

F1 · price: On December 12, 2022, Consonance Capital Master Account LP (the "Master Account"), Consonance Capital Opportunity Master Fund, LP ("Consonance Opportunity Master"), a certain managed account (the "Managed Account"), Consonance Life Sciences, LLC ("Consonance Life Sciences"), and Surrozen, Inc. (the "Issuer") entered into a Securities Purchase Agreement (the "Purchase Agreement"). Pursuant to the Purchase Agreement, Master Account agreed to sell to the Issuer 1,748,750 shares of common stock of the Issuer and warrants to purchase 582,916 shares of common stock of the Issuer for an aggregate purchase price of $874,375. Each warrant entitles the holder thereof to purchase one share of common stock of the Issuer at a price of $11.50 per share, subject to adjustment. The warrants are currently exercisable and will expire at the earlier of August 12, 2026, or upon redemption or liquidation.

F1 · derivative.exercise_date: On December 12, 2022, Consonance Capital Master Account LP (the "Master Account"), Consonance Capital Opportunity Master Fund, LP ("Consonance Opportunity Master"), a certain managed account (the "Managed Account"), Consonance Life Sciences, LLC ("Consonance Life Sciences"), and Surrozen, Inc. (the "Issuer") entered into a Securities Purchase Agreement (the "Purchase Agreement"). Pursuant to the Purchase Agreement, Master Account agreed to sell to the Issuer 1,748,750 shares of common stock of the Issuer and warrants to purchase 582,916 shares of common stock of the Issuer for an aggregate purchase price of $874,375. Each warrant entitles the holder thereof to purchase one share of common stock of the Issuer at a price of $11.50 per share, subject to adjustment. The warrants are currently exercisable and will expire at the earlier of August 12, 2026, or upon redemption or liquidation.

F1 · derivative.expiration_date: On December 12, 2022, Consonance Capital Master Account LP (the "Master Account"), Consonance Capital Opportunity Master Fund, LP ("Consonance Opportunity Master"), a certain managed account (the "Managed Account"), Consonance Life Sciences, LLC ("Consonance Life Sciences"), and Surrozen, Inc. (the "Issuer") entered into a Securities Purchase Agreement (the "Purchase Agreement"). Pursuant to the Purchase Agreement, Master Account agreed to sell to the Issuer 1,748,750 shares of common stock of the Issuer and warrants to purchase 582,916 shares of common stock of the Issuer for an aggregate purchase price of $874,375. Each warrant entitles the holder thereof to purchase one share of common stock of the Issuer at a price of $11.50 per share, subject to adjustment. The warrants are currently exercisable and will expire at the earlier of August 12, 2026, or upon redemption or liquidation.

F2 · ownership.nature: Consonance Capital Management LP ("Consonance Management") was an indirect beneficial owner of the securities reported herein that were held by the Master Account. Consonance Management is the investment adviser of the Master Account, and pursuant to an investment advisory agreement, Consonance Management exercises voting and investment power over the securities of the Issuer held by the Master Account. Consonance Capman GP LLC ("Capman") is the general partner of Consonance Management. Consonance Management receives an asset-based fee, but has no pecuniary interest.

F3 · ownership.nature: (Continued from Footnote 2) Mitchell Blutt is the manager and member of Capman and has a pecuniary interest in the securities held by the Master Account as the manager and member of the general partner of the Master Account and thereby is entitled to a portion of the profits allocation. Each of Dr. Blutt, Consonance Management and Capman disclaims beneficial ownership of the securities that were held by the Master Account except to the extent of their pecuniary interest therein.

SEC source: 0000899243-22-038571 · doc4.xml · nonDerivative · entry 4

BLUTT MITCHELL J MD · CIK 0001097955 · 10% owner

Soffer Benny · CIK 0001829318 · 10% owner

Livingston Kevin Harold · CIK 0001828234 · 10% owner

Consonance Capital Management LP · CIK 0001544773 · 10% owner

Consonance Capman GP, LLC · CIK 0001620428 · 10% owner

Consonance Life Sciences · CIK 0001824774 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Consonance Life Sciences, LLC

Disclosed balance after: 0

F9 · price: Pursuant to the Purchase Agreement, Consonance Life Sciences agreed to sell to the Issuer 1,885,000 shares of common stock of the Issuer and warrants to purchase 144,666 shares of common stock of the Issuer for an aggregate purchase price of $942,500. Each warrant entitles the holder thereof to purchase one share of common stock of the Issuer at a price of $11.50 per share, subject to adjustment. The warrants are currently exercisable and will expire at the earlier of August 12, 2026, or upon redemption or liquidation.

F10 · ownership.nature: Consonance Life Sciences is governed by a board of managers consisting of Mitchell J. Blutt, Benny Soffer and Kevin Livingston. As such, Mitchell J. Blutt, Benny Soffer and Kevin Livingston may be deemed to have voting and investment discretion over the securities held by Consonance Life Sciences and may be deemed to have shared beneficial ownership of such securities. Each of Mitchell J. Blutt, Benny Soffer and Kevin Livingston disclaims beneficial ownership of the securities that were held by Consonance Life Sciences except to the extent of their pecuniary interest therein. The Master Account, Consonance Opportunity Master and the Managed Account in the aggregate own the majority of the unit interests in Consonance Life Sciences.

SEC source: 0000899243-22-038571 · doc4.xml · nonDerivative · entry 3

BLUTT MITCHELL J MD · CIK 0001097955 · 10% owner

Soffer Benny · CIK 0001829318 · 10% owner

Livingston Kevin Harold · CIK 0001828234 · 10% owner

Consonance Capital Management LP · CIK 0001544773 · 10% owner

Consonance Capman GP, LLC · CIK 0001620428 · 10% owner

Consonance Life Sciences · CIK 0001824774 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Managed Account

Disclosed balance after: 0

F7 · price: Pursuant to the Purchase Agreement, the Managed Account agreed to sell to the Issuer 450,827 shares of common stock of the Issuer and warrants to purchase 150,275 shares of common stock of the Issuer for an aggregate purchase price of $225,413.50. Each warrant entitles the holder thereof to purchase one share of common stock of the Issuer at a price of $11.50 per share, subject to adjustment. The warrants are currently exercisable and will expire at the earlier of August 12, 2026, or upon redemption or liquidation.

F8 · ownership.nature: Consonance Management was an indirect beneficial owner of the securities reported herein that were held by the Managed Account. Consonance Management is the investment adviser of the Managed Account and exercises voting and investment power over the securities of the Issuer held by the Managed Account. Capman is the general partner of Consonance Management. Consonance Management receives an asset-based fee, but has no pecuniary interest. Mitchell Blutt is the manager and member of Capman. Each of Dr. Blutt, Consonance Management and Capman disclaims beneficial ownership of the securities that were held by the Managed Account except to the extent of their pecuniary interest therein.

SEC source: 0000899243-22-038571 · doc4.xml · nonDerivative · entry 2

BLUTT MITCHELL J MD · CIK 0001097955 · 10% owner

Soffer Benny · CIK 0001829318 · 10% owner

Livingston Kevin Harold · CIK 0001828234 · 10% owner

Consonance Capital Management LP · CIK 0001544773 · 10% owner

Consonance Capman GP, LLC · CIK 0001620428 · 10% owner

Consonance Life Sciences · CIK 0001824774 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Consonance Capital Opportunity Master Fund, LP

Disclosed balance after: 0

F4 · price: Pursuant to the Purchase Agreement, Consonance Opportunity Master agreed to sell to the Issuer 1,297,922 shares of common stock of the Issuer and warrants to purchase 432,639 shares of common stock of the Issuer for an aggregate purchase price of $648,961. Each warrant entitles the holder thereof to purchase one share of common stock of the Issuer at a price of $11.50 per share, subject to adjustment. The warrants are currently exercisable and will expire at the earlier of August 12, 2026, or upon redemption or liquidation.

F5 · ownership.nature: Consonance Management was an indirect beneficial owner of the securities reported herein that were held by Consonance Opportunity Master. Consonance Management is the investment adviser of Consonance Opportunity Master, and pursuant to an investment advisory agreement, Consonance Management exercises voting and investment power over the securities of the Issuer held by Consonance Opportunity Master. Capman is the general partner of Consonance Management.

F6 · ownership.nature: (Continued from Footnote 5) Consonance Management receives an asset-based fee, but has no pecuniary interest. Mitchell Blutt is the manager and member of Capman and has a pecuniary interest in the securities held by Consonance Opportunity Master as the manager and member of the general partner of Consonance Opportunity Master and thereby is entitled to a portion of the profits allocation. Each of Dr. Blutt, Consonance Management and Capman disclaims beneficial ownership of the securities that were held by Consonance Opportunity Master except to the extent of their pecuniary interest therein.

SEC source: 0000899243-22-038571 · doc4.xml · nonDerivative · entry 1

BLUTT MITCHELL J MD · CIK 0001097955 · 10% owner

Soffer Benny · CIK 0001829318 · 10% owner

Livingston Kevin Harold · CIK 0001828234 · 10% owner

Consonance Capital Management LP · CIK 0001544773 · 10% owner

Consonance Capman GP, LLC · CIK 0001620428 · 10% owner

Consonance Life Sciences · CIK 0001824774 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Consonance Capital Master Account LP

Disclosed balance after: 0

F1 · price: On December 12, 2022, Consonance Capital Master Account LP (the "Master Account"), Consonance Capital Opportunity Master Fund, LP ("Consonance Opportunity Master"), a certain managed account (the "Managed Account"), Consonance Life Sciences, LLC ("Consonance Life Sciences"), and Surrozen, Inc. (the "Issuer") entered into a Securities Purchase Agreement (the "Purchase Agreement"). Pursuant to the Purchase Agreement, Master Account agreed to sell to the Issuer 1,748,750 shares of common stock of the Issuer and warrants to purchase 582,916 shares of common stock of the Issuer for an aggregate purchase price of $874,375. Each warrant entitles the holder thereof to purchase one share of common stock of the Issuer at a price of $11.50 per share, subject to adjustment. The warrants are currently exercisable and will expire at the earlier of August 12, 2026, or upon redemption or liquidation.

F2 · ownership.nature: Consonance Capital Management LP ("Consonance Management") was an indirect beneficial owner of the securities reported herein that were held by the Master Account. Consonance Management is the investment adviser of the Master Account, and pursuant to an investment advisory agreement, Consonance Management exercises voting and investment power over the securities of the Issuer held by the Master Account. Consonance Capman GP LLC ("Capman") is the general partner of Consonance Management. Consonance Management receives an asset-based fee, but has no pecuniary interest.

F3 · ownership.nature: (Continued from Footnote 2) Mitchell Blutt is the manager and member of Capman and has a pecuniary interest in the securities held by the Master Account as the manager and member of the general partner of the Master Account and thereby is entitled to a portion of the profits allocation. Each of Dr. Blutt, Consonance Management and Capman disclaims beneficial ownership of the securities that were held by the Master Account except to the extent of their pecuniary interest therein.

SEC source: 0001593968-22-001520 · primary_01.xml · derivative · entry 5

Yeh Wen-Chen · CIK 0001873360 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,567

Underlying: Common Stock · 29,567 shares

Expires 2031-02-22

F1 · price: The reporting person agreed to cancellation of an option granted to him on February 23, 2021, in exchange for a new option having a lower exercise price.

F2 · derivative.exercise_date: The shares subject to the options vest and become exercisable in a series of 48 equal monthly installments beginning on 2/1/2021, subject to the reporting person's continued employment through the applicable vesting date.

SEC source: 0001593968-22-001520 · primary_01.xml · derivative · entry 4

Yeh Wen-Chen · CIK 0001873360 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,562

Underlying: Common Stock · 5,562 shares

Expires 2031-02-22

F1 · price: The reporting person agreed to cancellation of an option granted to him on February 23, 2021, in exchange for a new option having a lower exercise price.

F2 · derivative.exercise_date: The shares subject to the options vest and become exercisable in a series of 48 equal monthly installments beginning on 2/1/2021, subject to the reporting person's continued employment through the applicable vesting date.

SEC source: 0001593968-22-001520 · primary_01.xml · derivative · entry 2

Yeh Wen-Chen · CIK 0001873360 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,562 shares

Expires 2031-02-22

F1 · price: The reporting person agreed to cancellation of an option granted to him on February 23, 2021, in exchange for a new option having a lower exercise price.

F2 · derivative.exercise_date: The shares subject to the options vest and become exercisable in a series of 48 equal monthly installments beginning on 2/1/2021, subject to the reporting person's continued employment through the applicable vesting date.

SEC source: 0001593968-22-001520 · primary_01.xml · derivative · entry 1

Yeh Wen-Chen · CIK 0001873360 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 29,567 shares

Expires 2031-02-22

F1 · price: The reporting person agreed to cancellation of an option granted to him on February 23, 2021, in exchange for a new option having a lower exercise price.

F2 · derivative.exercise_date: The shares subject to the options vest and become exercisable in a series of 48 equal monthly installments beginning on 2/1/2021, subject to the reporting person's continued employment through the applicable vesting date.

SEC source: 0001593968-22-001519 · primary_01.xml · derivative · entry 8

Parker Craig C · CIK 0001526064 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,065

Underlying: Common Stock · 2,065 shares

Expires 2031-08-12

SEC source: 0001593968-22-001519 · primary_01.xml · derivative · entry 7

Parker Craig C · CIK 0001526064 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 181,270

Underlying: Common Stock · 181,270 shares

Expires 2031-08-12

SEC source: 0001593968-22-001519 · primary_01.xml · derivative · entry 6

Parker Craig C · CIK 0001526064 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 315,310

Underlying: Common Stock · 315,310 shares

Expires 2031-02-22

SEC source: 0001593968-22-001519 · primary_01.xml · derivative · entry 5

Parker Craig C · CIK 0001526064 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,987

Underlying: Common Stock · 35,987 shares

Expires 2031-02-22

SEC source: 0001593968-22-001519 · primary_01.xml · derivative · entry 4

Parker Craig C · CIK 0001526064 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 315,310 shares

Expires 2031-02-22

F1 · price: The reporting person agreed to cancellation of an option granted to him on 2/23/2021, in exchange for a new option having a lower exercise price.

F2 · derivative.exercise_date: The shares subject to the options vest and become exercisable in a series of 48 equal monthly installments beginning on 2/1/2021, subject to the reporting person's continued employment through the applicable vesting date.

SEC source: 0001593968-22-001519 · primary_01.xml · derivative · entry 3

Parker Craig C · CIK 0001526064 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 181,270 shares

Expires 2031-08-12

F3 · price: The reporting person agreed to cancellation of an option granted to him on 8/12/2021, in exchange for a new option having a lower exercise price.

F4 · derivative.exercise_date: Twenty-five percent of the shares subject to the Stock Option vests on 8/12/2022, and the remainder vests in 36 equal monthly installments thereafter for the following three years.

SEC source: 0001593968-22-001519 · primary_01.xml · derivative · entry 2

Parker Craig C · CIK 0001526064 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,065 shares

Expires 2031-08-12

F3 · price: The reporting person agreed to cancellation of an option granted to him on 8/12/2021, in exchange for a new option having a lower exercise price.

F4 · derivative.exercise_date: Twenty-five percent of the shares subject to the Stock Option vests on 8/12/2022, and the remainder vests in 36 equal monthly installments thereafter for the following three years.

SEC source: 0001593968-22-001519 · primary_01.xml · derivative · entry 1

Parker Craig C · CIK 0001526064 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 35,987 shares

Expires 2031-02-22

F1 · price: The reporting person agreed to cancellation of an option granted to him on 2/23/2021, in exchange for a new option having a lower exercise price.

F2 · derivative.exercise_date: The shares subject to the options vest and become exercisable in a series of 48 equal monthly installments beginning on 2/1/2021, subject to the reporting person's continued employment through the applicable vesting date.

SEC source: 0001593968-22-001521 · primary_01.xml · derivative · entry 8

Williams Charles O · CIK 0001325818 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 77,972

Underlying: Common Stock · 77,972 shares

Expires 2030-12-13

F1 · price: The reporting person agreed to cancellation of an option granted to him on 12/14/2020, in exchange for a new option having a lower exercise price.

F2 · derivative.exercise_date: Twenty-five percent of the shares subject to the Stock Option vests on 11/30/2021, and the remainder vests in 36 equal monthly installments thereafter for the following three years.

SEC source: 0001593968-22-001521 · primary_01.xml · derivative · entry 7

Williams Charles O · CIK 0001325818 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,433

Underlying: Common Stock · 2,433 shares

Expires 2031-08-12

F3 · price: The reporting person agreed to cancellation of an option granted to him on 8/12/2021, in exchange for a new option having a lower exercise price.

F4 · derivative.exercise_date: Twenty-five percent of the shares subject to the Stock Option vests on 8/12/2022, and the remainder vests in 36 equal monthly installments thereafter for the following three years.